Eli Lilly and Company (NYSE:LLY) Trading Up 2.3% – Time to Buy?

Eli Lilly and Company (NYSE:LLY)’s stock price was up 2.3% during trading on Wednesday . The company traded as high as $961.14 and last traded at $952.2350. Approximately 2,565,046 shares traded hands during mid-day trading, a decline of 19% from the average daily volume of 3,178,988 shares. The stock had previously closed at $931.09.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval for Lilly’s oral weight‑loss drug Foundayo has triggered bullish takeaways about revenue potential and re‑rated earnings outlooks. Great News for Eli Lilly Stock Investors!
• Positive Sentiment: An analyst price‑target lift and inclusion in “best buy” lists after the Foundayo approval supports upside expectations for sales and valuation. Price Target Raised Following FDA Approval for Fundayo
• Positive Sentiment: CEO Dave Ricks says Lilly is prepared to scale production of its new weight‑loss pill, reducing execution risk around supply constraints that could otherwise limit near‑term sales. LLY CEO Says Company Ready to Scale Production of Weight‑Loss Pill
• Positive Sentiment: Lilly extended its collaboration with AC Immune to advance next‑generation tau aggregation inhibitors, diversifying the pipeline into Alzheimer’s and supporting long‑term growth beyond obesity/diabetes. Eli Lilly Extends AC Immune Tau Pact
• Neutral Sentiment: Heightened investor attention and media coverage around Lilly (search/interest data) is driving volume and volatility but is mixed in directional impact. Investors Heavily Search Eli Lilly and Company
• Neutral Sentiment: Industry‑wide M&A and pipeline deals continue to reshape pharma dynamics; Lilly is an active participant but broader sector moves may be offsetting. Pharma, Biotech Giants Ramp Up M&A in Q1
• Negative Sentiment: Price competition intensified as Novo Nordisk launched a high‑dose Wegovy at a materially lower cash price (reported ~40% lower on some listings), which could pressure Foundayo adoption and pricing power. Novo Nordisk Unveils $399 Wegovy HD
• Negative Sentiment: Coverage notes the new Wegovy high‑dose listing is roughly $50 cheaper than Lilly’s competing branded option, highlighting near‑term market share and margin risk. A High Dose of Wegovy Will Cost $50 Less Than Zepbound
• Negative Sentiment: An analyst downgrade prompted short‑term selling and reflects concern about competitive pricing, side‑effect headlines and how much obesity upside is already priced in. LLY Trading Down on Analyst Downgrade
• Negative Sentiment: Some outlets flagged immediate investor worries after Foundayo approval — citing safety/side‑effect concerns and competitive intensity — which helps explain intra‑day volatility despite the approval. LLY Stock Dips Following FDA Approval of Foundayo

Analyst Ratings Changes

A number of equities research analysts have recently commented on LLY shares. The Goldman Sachs Group set a $1,260.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Scotiabank reaffirmed an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a report on Thursday, February 5th. Royal Bank Of Canada started coverage on shares of Eli Lilly and Company in a report on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 target price for the company. CICC Research upped their target price on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Finally, Cantor Fitzgerald upped their target price on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,222.22.

Eli Lilly and Company Stock Up 2.3%

The stock has a market capitalization of $899.69 billion, a PE ratio of 41.49, a PEG ratio of 1.09 and a beta of 0.51. The firm’s fifty day moving average is $988.75 and its 200-day moving average is $973.25. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LLY. 10Elms LLP grew its position in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares during the period. M.E. Allison & CO. Inc. grew its position in Eli Lilly and Company by 0.7% during the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock worth $1,587,000 after buying an additional 10 shares during the period. Tanager Wealth Management LLP raised its holdings in Eli Lilly and Company by 2.6% during the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock worth $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC raised its holdings in Eli Lilly and Company by 1.5% during the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after purchasing an additional 10 shares during the last quarter. Finally, Wealthspan Partners LLC boosted its position in Eli Lilly and Company by 0.5% during the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after purchasing an additional 10 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.